Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Familial chronic lymphocytic leukemia (CLL) constitutes 5-7% of CLL and has previously shown a more aggressive pattern of evolution compared to sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter case-control study aimed to compare clinical features, molecular biomarkers, and patient outcomes of familial and sporadic CLL. Adult CLL patients were enrolled from 18 Italian centers, with familial CLL defined as having at least one first-degree relative affected by CLL. Sporadic CLL patients were matched for gender and age at diagnosis within 4 years (1:2 ratio). Kaplan-Meier method was used to evaluate time-to-event outcomes. Of 480 enrolled patients, 160 had familial CLL, 320 sporadic CLL. Significant clinical and molecular differences between familial and sporadic CLL included the presence of lymphadenopathies at diagnosis >5 cm (7.2% vs 2.8%, p=0.027) and unmutated IGHV gene (55.5% vs 36.2% (p<0.001). First-line and second-line treatments were required in 55.6% and 46.1% of familial CLL and 43.1% (p=0.001) and 29.6% (p=0.034) of sporadic CLL, respectively. Both time to first treatment (TTFT) and time to next treatment (TTNT) were shorter for familial CLL than for sporadic CLL [median TTFT 66 months (95% CI: 36.7-95.2); vs 108 months (95% CI: 76.0-140.0), p=0.005; median TTNT 60 months (95% CI: 42.9-77.1) vs 94 months (95% CI: 43.7-144.3), p=0.030, respectively], although familiarity has not emerged as an independent prognostic factor. No difference in OS was observed. Considering the more aggressive course of familial CLL but the similar OS, CLL screening in relatives is not recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/bloodadvances.2025016546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Familial chronic lymphocytic leukemia (CLL) constitutes 5-7% of CLL and has previously shown a more aggressive pattern of evolution compared to sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter case-control study aimed to compare clinical features, molecular biomarkers, and patient outcomes of familial and sporadic CLL. Adult CLL patients were enrolled from 18 Italian centers, with familial CLL defined as having at least one first-degree relative affected by CLL.
View Article and Find Full Text PDFRapidly progressive locked-in syndrome secondary to atypical herpes simplex virus-1 rhombencephalitis in an immunocompromised individual.
IDCases
July 2024
UCLA Medical Center, Los Angeles, CA, USA.
HSV-1 encephalitis (HSE) is the most common cause of fatal sporadic encephalitis in the United States. HSE in adults is most commonly due to the reactivation of HSV in the central nervous system (CNS) which results in CNS necrosis leading to neurological compromise. The most common symptoms include altered mentation, fever, seizures, and focal neurological deficits.
View Article and Find Full Text PDFYttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases.
Blood Lymphat Cancer
October 2023
Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.
Radioimmunotherapy (RIT) with radio-labeled monoclonal antibodies to CD20 produces a high response rate in patients with low-grade B-cell lymphomas. The use of this modality in patients with chronic lymphocytic leukemia (CLL) has been sporadic in clinical trials and was hampered by the extensive marrow involvement seen commonly in patients with CLL, which would produce a high risk for marrow aplasia after treatment with RIT. Herein, we report our experience with RIT in 5 patients with CLL or SLL showing short-lived responses and significant myelosuppression.
View Article and Find Full Text PDFClinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.
Lancet Diabetes Endocrinol
May 2023
Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address:
Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising from other locations (eg, adrenal medulla, para-aortic, cardiac or thoracic, and pelvic). Given the higher risk of tumour multifocality and bilaterality for phaeochromocytomas and paragangliomas (PPGLs) because of SDHD pathogenic variants than for their sporadic and other genotypic counterparts, the management of patients with SDHD PPGLs is clinically complex in terms of imaging, treatment, and management options. Furthermore, locally aggressive disease can be discovered at a young age or late in the disease course, which presents challenges in balancing surgical intervention with various medical and radiotherapeutic approaches.
View Article and Find Full Text PDFAortic Cellular Diversity and Quantitative Genome-Wide Association Study Trait Prioritization Through Single-Nuclear RNA Sequencing of the Aneurysmal Human Aorta.
Arterioscler Thromb Vasc Biol
November 2022
Division of Vascular and Endovascular Surgery (E.L.C.), Massachusetts General Hospital, Boston.
Background: Mural cells in ascending aortic aneurysms undergo phenotypic changes that promote extracellular matrix destruction and structural weakening. To explore this biology, we analyzed the transcriptional features of thoracic aortic tissue.
Methods: Single-nuclear RNA sequencing was performed on 13 samples from human donors, 6 with thoracic aortic aneurysm, and 7 without aneurysm.